JY
PRME icon

Jeff Yass’s Prime Medicine PRME Stock Holding History

Jeff Yass’s Portfolio PRME Stock Details PRME Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$2.39M Sell
648,479
-67,350
-9% -$224K ﹤0.01% 6080
2026
Q1 		$2.49M Sell
715,829
-460,898
-39% -$1.75M ﹤0.01% 5660
2025
Q4 		$4.08M Buy
1,176,727
+592,303
+101% +$2.63M ﹤0.01% 4349
2025
Q3 		$3.24M Buy
584,424
+101,696
+21% +$413K ﹤0.01% 4829
2025
Q2 		$1.19M Buy
482,728
+340,109
+238% +$524K ﹤0.01% 6989
2025
Q1 		$284K Buy
142,619
+105,567
+285% +$269K ﹤0.01% 10174
2024
Q4 		$108K Sell
37,052
-78,002
-68% -$274K ﹤0.01% 11279
2024
Q3 		$445K Buy
115,054
+9,162
+9% +$42.4K ﹤0.01% 8749
2024
Q2 		$544K Buy
105,892
+84,580
+397% +$513K ﹤0.01% 8065
2024
Q1 		$149K Sell
21,312
-25,273
-54% -$192K ﹤0.01% 10908
2023
Q4 		$413K Buy
+46,585
New +$359K ﹤0.01% 9114
2023
Q3 		– Sell
-12,254
Closed -$180K – 12759
2023
Q2 		$180K Buy
+12,254
New +$171K ﹤0.01% 10393

Other funds holding PRME

AI
Alphabet Inc Mountain View, California $99.1B AUM 124.46% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
AIM
ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
CC
Casdin Capital New York $2B AUM 147.21% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return

Jeff Yass's PRME Position: Q2 2026 in Review

Jeff Yass reduced its Prime Medicine (PRME) stake by 9.4% in Q2 2026, selling an estimated $224K and leaving 648,479 shares worth $2.39M. The position accounts for ﹤0.01% of the portfolio, ranked #6080.

Jeff Yass first reported a position in PRME in Q2 2023 and has held it in 12 quarters since. The position peaked at $4.08M in Q4 2025. 186 funds tracked by Wall St. Rank hold PRME as of Q2 2026.

  • Jeff Yass held 648,479 shares of Prime Medicine worth $2.39M as of Q2 2026.
  • Jeff Yass sold 67,350 Prime Medicine shares in Q2 2026, an estimated $224K.
  • Prime Medicine made up ﹤0.01% of Jeff Yass's portfolio in Q2 2026, its #6080 holding.
  • Jeff Yass first reported a position in Prime Medicine in Q2 2023 and has held it in 12 quarters since.
  • Jeff Yass's Prime Medicine position peaked at $4.08M in Q4 2025.
  • 186 funds tracked by Wall St. Rank held Prime Medicine as of Q2 2026.

Based on Susquehanna International Group's 13F filing for Q2 2026, filed 14 Aug 2026.